Sofosbuvir is a nucleotide analog polymerase inhibitor, the first FDA-approved all-oral treatment for patients with HCV genotypes 2 or 3.
The drug received approval shortly after simeprevir, an Olysio, Janssen Therapeutics drug for patients with HCV genotype 1.
Sofosbuvir is a product of Gilead Sciences.
More Articles on Supply Chain:
FDA Gives 510(k) Clearance to Therapy Cool Flex Ablation Catheter
FDA Issues Draft Guidance on Custom Device Exemption Implementation
FDA Approves First Gel Sealant for Leaking Cornea After Cataract Surgery
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
